Payload Information
General Information of This Payload
| Payload ID | PAY0ZLSTM |
|||||
|---|---|---|---|---|---|---|
| Name | SC-DR002 |
|||||
| Synonyms |
SC DR002; SCDR002
Click to Show/Hide
|
|||||
| Target(s) | Human Deoxyribonucleic acid (hDNA) | |||||
| Structure |
|
|||||
| Formula | C33H26N4O7 |
|||||
| Isosmiles | [H][C@@]12CC([C])=CN1C(=O)c1cc(O[C])c(OCCCCCOc3cc4c(cc3O[C])C(=O)N3C=C([C])C[C@@]3([H])C=N4)cc1N[C@H]2O |
|||||
| InChI |
InChI=1S/C33H26N4O7/c1-19-10-21-16-34-24-14-29(27(41-3)12-22(24)32(39)36(21)17-19)43-8-6-5-7-9-44-30-15-25-23(13-28(30)42-4)33(40)37-18-20(2)11-26(37)31(38)35-25/h12-18,21,26,31,35,38H,5-11H2/t21-,26-,31-/m0/s1
|
|||||
| InChIKey |
CFCZGRPHLJYMQZ-JPYDJGNCSA-N
|
|||||
| IUPAC Name |
.
|
|||||
| Pharmaceutical Properties | Molecule Weight |
590.592 |
Polar area |
122.16 |
||
Complexity |
590.1801492 |
xlogp Value |
3.99626 |
|||
Heavy Count |
44 |
Rot Bonds |
10 |
|||
Hbond acc |
9 |
Hbond Donor |
2 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Tamrintamab pamozirine [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Partial Response (PR) |
1.72%
|
|||
| Patients Enrolled |
Female patients (age 18 years) with EOC if they had evidence of progressive disease during or within 6 months of receiving a platinum regimen.
|
||||
| Administration Dosage |
1 of 6 dose levels (0.025-0.40 mg/kg) every 3 weeks (Q3W), utilizing a standard 3+3 design (dose-limiting toxicity [DLT] period: 21 days).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02539719 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1a/1b dose escalation and expansion study of SC-003 as a single-agent and in combination with ABBV-181 in subjects with platinum-resistant/ refractory ovarian cancer.
|
||||
| Primary Endpoint |
The MTD for the Q3W schedule was 0.30 mg/kg and the SC-003 doses selected for the dose-expansion phase of the study were 0.30 mg/kg and 0.20 mg/kg.
|
||||
| Other Endpoint |
ORR=5.17% (N=3/58), 3 patients achieved PR. All responses were observed at 0.20-0.30mg/kg. Responses were not durable, with only 1 PR confirmed on the follow-up 16-week scan.
|
||||
References